Physician profile
Stephen Newman
NPI 1164497129
$1,940.67
in general payments reported to CMS, 2019-2025
25 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.42 · 2021: $184 · 2022: $268 · 2023: $159 · 2024: $1,069 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $700 · Food and Beverage: $406 · Consulting Fee: $200 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $700.00 |
| Food and Beverage | $405.77 |
| Consulting Fee | $200.00 |
| Education | $169.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eko Health, INC. | $800.00 | 2022-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $200.00 | 2025 | Lumryz |
| Harmony Biosciences LLC | $147.61 | 2023-2024 | Wakix |
| Jazz Pharmaceuticals INC. | $132.71 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.67 | 2021 | |
| Insmed, INC. | $99.65 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $58.00 | 2022-2024 | Airsupra, Breztri, Tezspire |
| Grifols USA, LLC | $36.04 | 2023-2024 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $35.94 | 2024 | Eohilia, Glassia |
| Actelion Pharmaceuticals US, INC. | $35.02 | 2024-2025 | Opsumit |
| Qol Medical, LLC | $32.06 | 2021-2024 | Sucraid |
| Beone Medicines USA, INC. | $27.84 | 2025 | Brukinsa |
| Daiichi Sankyo INC. | $23.73 | 2022 | |
| Merck Sharp & Dohme LLC | $21.37 | 2024 | Recarbrio, Dificid, Zerbaxa |
| Advanced Respiratory, INC | $19.51 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $18.41 | 2022 | |
| Aimmune Therapeutics, INC. | $17.18 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.27 | 2024 | Xarelto |
| Lilly USA, LLC | $15.96 | 2024 | Zepbound, Omvoh |
| Intercept Pharmaceuticals, INC. | $15.38 | 2023 | Ocaliva |
| Janssen Biotech, INC. | $14.54 | 2022 | |
| Baxter Healthcare | $13.55 | 2024 | |
| Mylan Specialty L.P. | $13.50 | 2021 | |
| Novo Nordisk INC | $12.42 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.